ライフサイエンスコーパス: dose

1 agent (ie, CRO 250 mg, intramuscular single dose).

2 ed dosing than among those receiving a fixed dose.

3 Cs at D30, with no increase after the second dose.

4 nsitization success or successfully consumed dose.

5 rnal capsule, not explained by antipsychotic dose.

6 starting concomitantly with the first taxane dose.

7 e points (95% CI, -47 to -16) for the 100-mg dose.

8 rate as effectively as the standard clinical dose.

9 stence of functional B cells after the third dose.

10 in part B were given the recommended phase 2 dose.

11 r of the Akt-beta-catenin interaction at low doses.

12 generally being well tolerated at prescribed doses.

13 by intravenous heroin at low, human-relevant doses.

14 IT therapy was given for a total of 21 to 26 doses.

15 hibiting adverse side effects at therapeutic doses.

16 ine and lower but significant VE with 1 or 2 doses.

17 each dose group between weight-band and flat-dosing.

18 median AUC0-24h compared to the weight-band dosing.

19 onged control of tumors through intermittent dosing.

20 Blood samples were collected for 96 h after dosing.

21 effects of naloxone-methiodide at a very low dose (0.2 mg/kg; at which naloxone was undetectable in b

22 n showed that SUVs remain stable down to 1/3 dose (1.2 MBq/kg).

23 age points (95% CI, -40 to -5) for the 40-mg dose, -19 percentage points (95% CI, -35 to 2) for the 6

24 nt with OLINDA/EXM 2.0 (commercial) and IDAC-Dose 2.1 (free) software.

25 ), and mean FIA [+/-SD](%) from the baseline dose [23.3 (10.9)] was greater than that from the consec

26 Addition to wine required high doses (25-32 g/L) for protein removal and haze preventio

27 ence interval [CI], -18 to 27) for the 20-mg dose, -25 percentage points (95% CI, -40 to -5) for the

28 ols with drug-sensitive TB received standard dose (5 mg/kg/day).

29 eated with definitive chemoradiation (median dose 50.4 Gy) followed by resection within 4 months.

30 those who did and did not miss 7 consecutive doses (92% vs 93%, P = .897).

31 nously over 2 h, l-folinic acid (175 mg flat dose administered intravenously over 2 h) or d,l-folinic

32 y over 2 h) or d,l-folinic acid (350 mg flat dose administered intravenously over 2 h), and fluoroura

33 ling, and (2) immunogenicity of 2 additional doses administered 10Y post-initial vaccination.

34 osing based on a hemoglobin-based, titration-dose algorithm in such patients might reduce risks assoc

35 articipants nor investigators were masked to dose allocation.

36 A short-term increase in the ICS dose alone for worsening of asthma symptoms is not recom

37 Low-dose AMPH contracted these trajectories and reduced thei

38 ies and reduced their variance, whereas high-dose AMPH expanded both.

39 ting for up to 2 weeks after the larger MCAM dose and <1 day after naltrexone.

40 g correlation between the lipopolysaccharide dose and (64)Cu-LLP2A uptake, as quantified by in vivo P

41 of CD8(+) T cell Ag recognition, in which Ag dose and affinity do not provide any additional response

42 tion with lanadelumab started from the first dose and continued throughout the entire study period.

43 g treatment on and off can reduce cumulative dose and limit toxicities.

44 estimated using a model based on infectious dose and the sensitivity of nucleic acid testing.

45 st+ and Pvalb+ subtypes in the mPFC produced dose and time-dependent antidepressant effects in the fo

46 k is required to assess the influence of the dose and timing on blood levels.

47 nstrated a negative correlation between IVIG dose and toxin-triggered T-cell proliferation (r = -.67,

48 measurements correlated with both radiation dose and visual acuity.

49 might reduce risks associated with high ESA doses and decrease the cumulative exposure-while reducin

50 otensin II reduced catecholamine vasopressor doses and had an apparent effect in reducing endogenous

51 voir potential of well over a year at mg/day dosing and may not require cold chain storage for global

52 tage points (95% CI, -35 to 2) for the 60-mg dose, and -33 percentage points (95% CI, -47 to -16) for

53 d vaccination, particularly with the highest dose, and three participants (21%) in the 250-mug dose g

54 s demonstrated that chemoprophylaxis, or low-dose anticoagulation, prevents VTE in selected medical i

55 The results show that the median dose area product (DAP) for CVAD insertion is 0.7Gy.cm(2

56 Median exposure (dose area product/kg) was decreased by 30% for all proce

57 porating model error that shifts the TGFbeta doses associated with the state transitions and reproduc

58 intravenously every 3 weeks (8 mg/kg loading dose at first cycle, and 6 mg/kg thereafter) for 18 dose

59 or damage, effectively boosting the local RT dose at the tumor.

60 s greater than that from the consecutive day dose (at 24 h) [20.1 (10.4); P = 0.042] but did not diff

61 2] but did not differ from the alternate day dose (at 48 h) [20.9 (13.4); P = 0.145].

62 at other loci and sensitize tissues to gene dose based upon signal duration.

63 Whether using a low fixed ESA dose versus dosing based on a hemoglobin-based, titration-dose algor

64 ot have diuretics, 2195 (33.1%) had diuretic doses between 1 and 40 mg/day, and 1085 (16.4%) had diur

65 Lifelong exposure of rats to low-dose BPA at 25 and 250 mug/kg BW/d altered the estrous c

66 ine, after pulmonary embolism and after each dose by biventricular pressure-volume loops, invasive pr

67 Individualized FC dose calculation included weight, bypass circuit volume,

68 ort treated with cyclophosphamide equivalent dose (CED) >=4,000 mg/m(2).

69 -CD20 therapy), were not candidates for high-dose chemotherapy and subsequent autologous stem-cell tr

70 lls but began to decline after 3 to 6 weekly doses, coincident with the development of antidrug antib

71 dolutegravir 50 mg; or once-daily oral fixed-dose combination of tenofovir disoproxil fumarate 300 mg

72 e randomly assigned to once-daily oral fixed-dose combination tenofovir alafenamide 25 mg and emtrici

73 al dolutegravir 50 mg; once-daily oral fixed-dose combination tenofovir disoproxil fumarate 300 mg an

74 At this l-fucose dose, complement activation and acute post-ischemic kidn

75 Low-dose CT enabled significant radiation dose reduction.

76 nts completed 4 cycles of paclitaxel without dose delay, the regimen would be considered feasible.

77 The real-time control of the ultrasound dose delivered through the skull is necessary as the ran

78 We investigated the dose dependence of the impairment in oculomotor and ocul

79 nsitive nanoparticles (CGPU) displayed a GSH-dose dependent release of cisplatin.

80 that rhbeta-gal uptake by the fibroblasts is dose-dependent and saturable and can be competitively in

81 Below 10 ug/ml, there were no dose-dependent cellular ROS increases or effects in MEA

82 However, a dose-dependent deformability increase upon latrunculin B

83 annel blocker of HCNs-for 24 h resulted in a dose-dependent higher HRV and lower heart rate at 5 days

84 ounds in the cochlea, rather cisplatin had a dose-dependent impact on cochlear clock rhythms only aft

85 nsitive male NSCLC cell lines demonstrated a dose-dependent induction of linc-SPRY3-2/3/4 following i

86 le administration of (212)Pb-L2 demonstrated dose-dependent inhibition of tumor growth in the PSMA(+)

87 bladder epithelial progenitor cell line in a dose-dependent manner, achieving far higher efficiency a

88 rmone levels in both dams and offspring in a dose-dependent manner, but did not change TSH levels, we

89 xpansion and restorative division rates in a dose-dependent manner, leading to tumorous overprolifera

90 enocepacia and P. aeruginosa in CF MDMs in a dose-dependent manner.

91 ere inhibited by LJM17, LJM11, and DSG1 in a dose-dependent manner.

92 Similarly, there was no dose-dependent relationship between PPS exposure and dia

93 Similar dose-dependent relationships were observed for subjectiv

94 Dose-dependent repression of methionine adenosyltransfer

95 h the highest lipase inhibition (~ 70%) in a dose-dependent way.

96 All four proteins specifically and dose dependently adhered to bovine fibrinogen.

97 RPamide neuropeptides dose-dependently activate the GnRH/AKH-like receptors GN

98 or, immediately after the extinction session dose-dependently impaired the consolidation of fear exti

99 The tracer accumulates dose-dependently in GLP-1R-positive tumors.

100 In cynomolgus monkeys, ARGX-117 dose-dependently reduces free C2 levels and classical pa

101 Short-term incubation with IL-3 dose-dependently upregulated MRGPRX2 expression in both,

102 Low agonist doses did not cause maternal anemia but still adversely

103 Whether effects of daily or weekly dosing differ requires further study.

104 he model overestimated inactivation by small-dose DUV on wet SS.

105 al, which randomized patients to either high-dose eplerenone or placebo for 26 weeks.

106 Subsequent treatment with low-dose EPO triggered robust RBC production in both models.

107 Dose-escalated radiotherapy (RT) with androgen-deprivati

108 ere locoregional control, local control with dose-escalated RT, pattern of failure, and adverse effec

109 assigned to receive intravenous haloperidol dose escalation at 2 mg every 4 h, neuroleptic rotation

110 ongoing placebo-controlled, observer-blinded dose-escalation study (ClinicalTrials.gov identifier NCT

111 MTD was not reached (maximum dose evaluated, 200 mg twice a day); 150 mg once daily w

112 (0, 0.5, 1.0 mg) across three separate fixed dose experimental sessions.

113 Single-time-point dose factors for tumor were determined to be 11.0, 12.1,

114 s to examine the effect of low- and moderate-dose fiber-containing snack bars, comprising mainly chic

115 terns, namely to form a downslope and a flat dose field in the target.

116 At the dose of 10 mg/kg (600 mg for flat-dosing), flat-dosing resulted in higher median AUC0-24h

117 Plausible upper-bound, lifetime radiation dose for each boar was estimated from radioactivity leve

118 Patients from 46 centers were dosed for 12 or 24 weeks with or without ribavirin, in l

119 immunogenicity trial of qNIV (in 5 different doses/formulations) in healthy adults aged >=65 years.

120 compared as well as the variability of each dose group between weight-band and flat-dosing.

121 e of any of the eight animals in the 100-mug dose group by day 2 after challenge, and limited inflamm

122 and three participants (21%) in the 250-mug dose group reported one or more severe adverse events.

123 and 40 mg/day, and 1085 (16.4%) had diuretic doses >40 mg/day.

124 of TSH and decreased cAMP production at high doses (>1 mU/ml).

125 USA), with refractory agitation, despite low-dose haloperidol, were randomly assigned to receive intr

126 ive, and no relationship to the administered dose has been documented.

127 e on day 3 (10.5 +/- 4.1 percentage injected dose [%ID]/g vs. 3.8 +/- 0.9 %ID/g, P < 0.001) and on da

128 contrast, alveolospheres pretreated with low-dose IFNs show a reduction in viral replication, suggest

129 ter) for 18 doses or weekly (4 mg/kg loading dose in the first week, and 2 mg/kg thereafter) for 9 we

130 Seroconversion after 2 IPV doses in each arm were as follows: (A) 97.3% (90.6-99.7)

131 Upon oral dosing in rats, CAGE increased peak blood concentrations

132 blind, comparator-controlled (trivalent high-dose inactivated influenza vaccine [IIV3-HD], or quadriv

133 risk of CVDs associated with glucocorticoid dose intake even at lower doses (<5 mg) in 6 immune-medi

134 val (RFS) and overall survival (OS) for high-dose interferon alfa (HDI) and ipilimumab at 10 mg/kg (i

135 Low-dose interleukin-2 (IL-2) represents a new therapeutic a

136 soporous SNPs 466.0 +/- 86.0 nm) upon single dose intravenous administration to female and male BALB/

137 We report the effect of high-dose intravenous immunoglobulin (IVIg) on safety, tolera

138 his breakpoint presumes that AZI (1-g single dose) is used in an approved regimen that includes an ad

139 mages from SDCT is high and independent from dose, kernel, and denoising settings; however, shows a d

140 y and activity of liso-cel did not differ by dose level.

141 ccurred before CAR-NKT cell infusion, and no dose-limiting toxicities were observed.

142 Dose-limiting toxicity was not observed.

143 n treatment discontinuation, nondaily statin dosing lowered total cholesterol and LDL-C levels.

144 ls of Saa1 and Saa2 being comparable to high dose LPS.

145 ith glucocorticoid dose intake even at lower doses (<5 mg) in 6 immune-mediated diseases.

146 n chemical agents used as therapeutics, "the dose makes the poison," it is now realized that this apt

147 d treatments, number of IAC injections, drug dose, mean injection time, injection method (pulsatile v

148 e majority of the patients had received high-dose melphalan and stem cell transplantation and/or trea

149 Dose metrics for several structures (i.e., optic disc, m

150 n AD was comparable to that of radiobiologic dose metrics that involve more complex calculations.

151 oroalkyl sulfonates (PFSAs) were enriched in dosed mouse serum, suggesting in vivo transformation of

152 The maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D, primary o

153 m 0; p=0.655) in those who had received >=15 doses (n=20).

154 p=0.351 in the patients who had received <15 doses (n=34), and -0.0135+/-0.1332 (not significantly di

155 the islet viability, metabolic activity, and dose necessary to reverse diabetes.

156 n of (124)I-MIBG, we estimated the effective dose of (124)I-MIBG.

157 aimed to prospectively determine the lowest dose of (64)Cu-DOTATATE that facilitates diagnostic-qual

158 At the dose of 10 mg/kg (600 mg for flat-dosing), flat-dosing r

159 nuous 28-day schedule, to adults mostly at a dose of 100 mg twice daily, and to paediatric patients m

160 aily, and to paediatric patients mostly at a dose of 100 mg/m(2) (maximum of 100 mg) twice daily.

161 ovides high-quality and accurate images at a dose of 148 MBq (4.0 mCi) for the detection of somatosta

162 Cebranopadol at a low dose of 25 ug/kg (p.o.) did not induce significant hyper

163 Ribavirin was given at the median dose of 600 (range, 29-1200) mg/day (mean, 8.6 +/- 3.6 m

164 iral classes to add either fostemsavir (at a dose of 600 mg twice daily) or placebo to their failing

165 f Intralipid with half the standard clinical dose of Abraxane reduces the tumor growth rate as effect

166 n all participants who received at least one dose of any study drug, regardless of whether it was the

167 eport that all infants given either a single dose of bNAbs at 30 h, or a 21-day triple-drug ART regim

168 In patients with advanced CLL, a 5 x 10(8) dose of CART-19 may be more effective than 5 x 10(7) CAR

169 Single dose of D-Sino attenuated inflammation in the injured br

170 no differences in outcomes between standard dose of epinephrine and vasopressin alone or in combinat

171 on one randomized controlled trial, standard dose of epinephrine improved overall survival but not ne

172 us iron was administered as a single 1000 mg dose of ferric carboxymaltose in 100 mL normal saline, a

173 correlate significantly with the accumulated dose of gadoterate meglumine (P=0.9064; rho=-0.0164 [95%

174 D, primary outcome) is the FDA/EMEA approved dose of gemcitabine-nab-paclitaxel along-with ATRA (45 m

175 uration treatment with a clinically relevant dose of GS-9688 is well tolerated and can induce a susta

176 ior to infection, prevented against a lethal dose of HSV-2 infection in a murine model.

177 e 3 treatments in a random order: bolus 30-g dose of LNS (Bolus); 3 x 10-g doses of LNS (Divided); an

178 nical disease following exposure to a lethal dose of LPS.

179 ith the histological analysis reveals a safe dose of microcapsules (20 x 10(6)), which has not lead t

180 vivo, this can be accomplished with a single dose of p53 inhibitor at the commencement of BRAF/MEK in

181 1 month later by saline placebo or a single dose of PCV13 followed 1 month later by 23-valent polysa

182 e were randomized to receive either a single dose of PCV20 followed 1 month later by saline placebo o

183 A single intranasal dose of RSV/DeltaNS2/Delta1313/I1314L was evaluated in a

184 743 adults were enrolled; 741 received >=1 dose of study drug (DTG/3TC, N = 369; TAF-based regimen,

185 n all participants who received at least one dose of study drug in terms of treatment-emergent advers

186 ed in all patients who received at least one dose of study drug.

187 All enrolled patients received at least one dose of study treatment and thus were evaluable for 12-w

188 opulation included patients who received any dose of study treatment.

189 n all patients who had received at least one dose of study treatment.

190 tients were randomized, and 199 received >=1 dose of study treatment.

191 to receive either BCG, followed by a booster dose of tetanus-diphtheria-pertussis inactivated polio v

192 were observed in these models after a single dose of the ADC-46 (0.02 mumol/kg).

193 tudy, we investigated whether a single 10 mg dose of the GABA(B) agonist baclofen impaired motor sequ

194 t median magnitude detected after the second dose of vaccine.

195 In mice administered with a lethal dose of venomous PLA2, L&K-NPs also inhibit hemolysis an

196 e performed to estimate the human-equivalent doses of (+/-)-(11)C-YJH08.

197 e responsive to levodopa, and were on stable doses of anti-parkinsonian medication were eligible.

198 In an open-label titration phase, increasing doses of apomorphine sublingual film (10-35 mg) were adm

199 er deciliter, despite the receipt of maximum doses of background lipid-lowering therapy.

200 The present findings also revealed that high doses of BrdU lead to the activation of apoptotic cellul

201 els after treatment with clinically relevant doses of cisplatin.

202 did not reveal an association, but reported doses of corticosteroids in included studies were high (

203 ses of everolimus and nonsignificantly lower doses of cyclosporin A, resulting in significantly lower

204 In this work, we show that sublethal doses of doxorubicin and vorinostat still increased cell

205 inistration, and again on Day 10 after daily doses of either 4 mg (Cohorts 1 and 2), or 1 mg (Cohort

206 ion group received significantly lower daily doses of everolimus and nonsignificantly lower doses of

207 to fermentation required substantially lower doses of GSP (5 g/L) to prevent haze formation.

208 ficant VE against vaccine-type CIN2+ after 3 doses of HPV vaccine and lower but significant VE with 1

209 or severe asthma that are treated with high doses of inhaled corticosteroids.

210 ants were exposed to three different blinded doses of intranasally administered nicotine (0, 0.5, 1.0

211 er: bolus 30-g dose of LNS (Bolus); 3 x 10-g doses of LNS (Divided); and no LNS (Control), with contr

212 Higher doses of NAC reduced risk of macular loci sensitivity lo

213 We conclude that even low doses of natural bedrock radioactivity influence the mut

214 ICU patients who were given moderate-to-high doses of opioids and expected to remain alive and ventil

215 ending groups, randomized 2:1 to receive two doses of TAK-003 or placebo 90 days apart.

216 White rabbits were administered 3 sequential doses of the full-length gB protein with an MF59-like sq

217 High doses of the initial lead compound led to tumor stasis i

218 urve" with increasing cAMP production at low doses of TSH and decreased cAMP production at high doses

219 vity on Days 4 to 7 after the repeated daily dosing of the drug.

220 Meta-regression of the effect of dose on mortality did not reveal an association, but rep

221 ithelium, a valuable activity at therapeutic doses on a range of clinical pathogens, mediated by ener

222 toxicity, variable efficacy, and unsuitable dosing options.

223 first cycle, and 6 mg/kg thereafter) for 18 doses or weekly (4 mg/kg loading dose in the first week,

224 nal regimen (CsA CE 4 times daily [QID, high-dose] or CsA CE twice daily [BID, low-dose] + vehicle BI

225 A single high-dose oral administration of nCyp c 1 but not of mCyp c 1

226 ombination (CSR), while decreasing at higher doses over a broad physiological range, AID and Blimp1 e

227 f 4-6 reduction in imaging time (or injected dose) over the mCT Flow when using the ALROC metric for

228 ts associated with acenocoumarol maintenance dose (p < 0.05).

229 ontrols after adjusting for previous vaccine doses (P < .001).

230 ation, providing 33.90 +/- 9.06% of injected dose per gram of brain tissue (%ID/g) in the cortex and

231 +/- 0.2 and 3.04 +/- 0.3 percentage injected dose per gram, respectively) indicating that (18)F-FAC c

232 ine, HNK reduced NMDA receptor currents in a dose-, pH-, and voltage-dependent manner.

233 S; gemcitabine plus dacarbazine in LMS; high-dose prolonged-infusion ifosfamide in SS; etoposide plus

234 Pharmacokinetics were dose proportional and exceeded preclinical efficacious l

235 risk of, and associations with, SAE and high-dose radiation exposure using large-scale registry data.

236 ataracts in wild boar exposed to chronic low-dose radiation.

237 Dose-ranging efficacy studies were performed on a 1 T MR

238 ed serious adverse effects were found in the dose-ranging study in rats administered single- or two-d

239 andomized, double-blind, placebo-controlled, dose-ranging trial involving 286 patients with establish

240 human interleukin-2 (IL-2) combined with low-dose rapamycin to prolong graft survival.

241 ed cluster analysis to group patients by the dose, recency, duration, and continuity of use.

242 n and developed a therapeutic regimen of low-dose recombinant human interleukin-2 (IL-2) combined wit

243 ed noninferiority of once-daily 60 mg (30 mg dose-reduced) edoxaban compared with warfarin for preven

244 Low-dose CT enabled significant radiation dose reduction.

245 as well as simplification of the medication dosing regimen.

246 ng study in rats administered single- or two-dose regimens of S-2P combined with CpG 1018 alone or Cp

247 proximately 40% of patients in both exercise dosing regimens were classified as VO(2)peak responders

248 higher with the 10-mg and 25-mg brensocatib doses, respectively, than with placebo.

249 Dose response curves of ML385, an NRF2 inhibitor, showed

250 hich can operate to create an ultrasensitive dose response.

251 There were dose-response associations between steps, SB (inverse) a

252 Our analysis shows that the dose-response curve with the FSS data clearly differs fr

253 HR activation exhibits an "inverted U-shaped dose-response curve" with increasing cAMP production at

254 From the dose-response curves of mortality data created as a func

255 0a, Or22a and Or35a) showed a shift in their dose-response curves when Orco was co-integrated, reflec

256 ta sets combined showed significant negative dose-response for the accumbens, caudate, pallidum, puta

257 Random effects dose-response meta-analyses were used to estimate summar

258 e of 10 mg/kg (600 mg for flat-dosing), flat-dosing resulted in higher median AUC0-24h compared to th

259 tolerated dose (MTD) and recommended phase 2 dose (RP2D, primary outcome) is the FDA/EMEA approved do

260 (1) long-term immunogenicity of an initial 2-dose RZV schedule by following-up adults vaccinated at >

261 ce the study was stopped to enable a further dose saturation study in a porcine kidney model.

262 ments in procedural efficiency and radiation dose savings for targeting out-of-plane lesions.

263 h the same or a different statin (or a lower dose) seem to be favorable options for improving statin

264 rs of age), who were randomized to receive 2 doses-separated by 21 days-of 10 mug, 30 mug or 100 mug

265 narios), EPA's Stochastic Human Exposure and Dose Simulation (SHEDS)-Multimedia/Integrated Exposure U

266 Relative to the dosing solution, C6 and C7 perfluoroalkyl sulfonates (PF

267 ome end points included SER-287 engraftment (dose species detected in stool after but not before SER-

268 Diabetes was induced using the low-dose streptozotocin method.

269 omized, placebo-controlled, single ascending dose study consisting of 3 cohorts (40, 80, 120 mg MMV39

270 Dosing symptom frequency in participants who are BE-tole

271 ded clinically important impairment, and the doses tested may not represent common usage.

272 tly lower among children receiving escalated dosing than among those receiving a fixed dose.

273 ibit CD4 and CD8 T cell proliferation at the doses that are not related to increased cell death.

274 In timeframes beginning 30 days post-second dose, the primary endpoint (overall vaccine efficacy) wa

275 mence subcutaneous dupilumab (600 mg loading dose, then 300 mg once weekly for 15 weeks [n = 30], or

276 ed mutations infrequently emerged after high-dose therapy.

277 We show here that at low doses these SCFAs directly impact B cell intrinsic funct

278 re 0.7-fold (1-mug dose) to 3.5-fold (50-mug dose) those of the recovered individuals.

279 of OM BID, or to pharmacokinetically guided dose titration (OM-PK) for 20 weeks.

280 aqueous solubility allows delivery of higher doses to mice.

281 ention Trials Network (HPTN) 067/Alternative Dosing to Augment PrEP Pill Taking (ADAPT) Study evaluat

282 ng antibodies on day 43 were 0.7-fold (1-mug dose) to 3.5-fold (50-mug dose) those of the recovered i

283 All dose-to-imaging intervals showed significantly higher fl

284 ematologic toxicity resulted in more reduced dosing/treatment discontinuation in arm B vs arm C.

285 HRs for type-specific CVDs and <5.0-mg daily dose use were: 1.69 (95% CI 1.54-1.85) for atrial fibril

286 istal toe nerve fascicles at the vincristine dose used in this study.

287 A 2-dose UVV was demonstrated to be a cost-effective alterna

288 , high-dose] or CsA CE twice daily [BID, low-dose] + vehicle BID) and vehicle patients were allocated

289 Whether using a low fixed ESA dose versus dosing based on a hemoglobin-based, titratio

290 Withdrawal of VKAs and high-dose vitamin K2 improve vitamin K status in patients on

291 The calculated effective dose was 0.0141 mSv/MBq when using a 3.5-h voiding inter

292 a-secreting T-cells after a ChAd155-RSV high dose was 108.3/106 PBMCs at D30, with no increase after

293 The median parenchyma-absorbed dose was 37 Gy (range, 12-55 Gy).

294 nd its relationship with parenchyma-absorbed dose was assessed using linear models.

295 The inoculum dose was escalated, aiming to colonize at least 70% of p

296 eraction between ischemic time and alteplase dose was statistically significant (p = 0.018).

297 mographics, use of PPIs, duration of use and dose were recorded.

298 odds ratios for vaccination with 1, 2, and 3 doses were 0.53 (95% confidence interval (CI): 0.37, 0.7

299 Absorbed radiation doses were calculated.

300 n 32 (91%) of 35 participants after a single dose when measured in MNA(80) and in 35 (100%) participa

301 A 60-Gy radiation dose with concurrent chemotherapy should remain the stan